Recruiting

Observational Study

Sponsor:

Mayo Clinic

Code:

NCT02740634

Conditions

Atypical Alzheimer's Disease

Logopenic Progressive Aphasia (LPA)

Posterior Cortical Atrophy (PCA)

Alzheimer Disease

Alzheimer Disease, Early Onset

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Interventions

F-18 AV 1451

C-11 PiB

Study Details

Brief summary:

This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.

Conditions

Atypical Alzheimer's Disease

Logopenic Progressive Aphasia (LPA)

Posterior Cortical Atrophy (PCA)

Alzheimer Disease

Alzheimer Disease, Early Onset

Study ID

NCT02740634

Start date

May, 2016

Status verified date

Jul, 2026

Completion date

Mar, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Over the age of 21
  • Must have an informant who will be able to provide independent evaluation of functioning
  • English is primary language
  • All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
  • All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
  • All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain

Exclusion Criteria:

  • If you have had a stroke or tumor that could explain your symptoms
  • Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study
  • Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded
  • Subjects will be excluded if they have poor vision (20/400)
  • Women that are pregnant or post-partum and breast-feeding will be excluded
  • Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome
  • Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)

Study Design

Enrollment

60 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Tau PET Scan, F-18 AV 1451

All subjects will receive two Tau PET scans during this study.

experimental: PiB PET Scan, C-11 PiB

All subjects will receive two PiB PET scans during this study.

Interventions

F-18 AV 1451

Tau binding agent

C-11 PiB

Amyloid binding agent

Primary outcome measure

  • Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). [ Time Frame: 5 years ]
  • Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA). [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Sarah M Boland, CCRP

507-284-3863boland.sarah@mayo.edu

Locations

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Sarah Boland, CCRP

507-284-3863boland.sarah@mayo.edu

More Information

Sponsor

Mayo Clinic

Last update posted

Jul 17, 2026

Last verified

Jul, 2026

Keywords

  • PCA
  • LPA
  • AD
  • Amnestic AD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-07-17.